Eat2beNICE Vitamins and Nutrients as Supplementation for Impulsivity, Irritability, and Compulsivity (VANTASTIC)

  • End date
    Sep 30, 2022
  • participants needed
  • sponsor
    Radboud University
Updated on 5 March 2022


Impulsivity, irritability and compulsivity are cross-disorder symptom domains, which affect a significant proportion of adolescents.

Predominately as part of attention deficit hyperactivity disorder (ADHD) but also as symptom domains without a diagnosis of ADHD, impulsivity and irritability cause serious burden. Furthermore, treatment options and their effects are limited.

Previous studies with different study designs assessing micronutrients for the treatment of impulsivity / ADHD in children and adults have reported positive benefits as well as a very good tolerability. However, more research is required; in particular controlled studies with adolescents, cross-disorder approaches and studies investigating long-term effects are missing.

The focus of this study is to investigate the effect of micronutrients on impulsivity, irritability and compulsivity in children and adolescents between 11 and 18 years of age with a high level of impulsivity and irritability with or without a diagnosis of attention deficit hyperactivity disorder (ADHD).

The investigators intend to include 210 children and adolescents (n=110 in Germany) with a high level of impulsivity and irritability.

The study is divided in two phases. An initial 10-week double blind, placebo-controlled treatment phase with broad-spectrum micronutrients is followed by a 10-week open-label treatment phase. The study assessments will be performed during five study visits and a follow-up visit.

Condition Impulsive Behavior
Treatment Placebo, broad-spectrum micronutrient
Clinical Study IdentifierNCT03898336
SponsorRadboud University
Last Modified on5 March 2022


Yes No Not Sure

Inclusion Criteria

Male or female, aged 11;0 - 17; 6 years at initial inclusion
Subjects with a high level of impulsivity/ irritability based on a CGI-S-score 4 and a parent-rated Affective Reactivity Index (ARI) score 5 indicating a high level of multi-dimensional irritability
Subjects with or without a research diagnosis of attention deficit hyperactivity disorder (ADHD). ADHD has to be confirmed by structured diagnostic interview (ADHD section of Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS))
Deemed reliable and compliant with the protocol (including the ingestion of as many capsules as prescribed by the investigator)
Ability to comprehend and speak the native language of the country in which the assessments take place
Signed informed consent by parents or legal representative
Signed informed assent by child or adolescent (indicating that the subject is aware of the investigational nature and the core aspects of the study and the study is run in accordance with the ICH GCP guideline E6 (R2) (2016))

Exclusion Criteria

Subject is being treated with a medication that might, in the opinion of the investigator, pose a safety risk for the subject when participating in this study
Intellectual disability (based on available IQ or the clinical opinion of the investigator, taking into account relevant psychosocial information, e.g. educational level)
Any known abnormality of mineral metabolism (e.g., Wilson's disease, haemochromatosis)
History of or present clinically relevant somatic or psychiatric acute or chronic disorder that, in the opinion of the investigator, might confound the results of tolerability/safety assessment, or prohibit the patients from completing the study, or would not be in the best interest of the patient
Subject has a documented allergy, hypersensitivity, or intolerance to any of the ingredients of the investigational product
Subject has taken any kind of food supplement containing vitamins, minerals and/or trace elements within 30 days prior to entering the study
Subject has taken another investigational product or taken part in a clinical study within 30 days prior to entering the study
Subject has unstable treatment conditions (current changes in medication and/or psychotherapy) that might in the opinion of the investigator confound the results of the study with respect to impulsivity/irritability
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note